At a recent morning tea symposium held in conjunction with the Malaysian Urological Conference 2016, Dr Marie Carmela Lapitan discussed about the benefits of combination therapy with alpha-blockers and 5-alpha-reductase inhibitors (5-ARIs) for the management of benign prostatic hyperplasia (BPH).
Recently, at a Pfizer-sponsored continuing medical education event, Dr Steven Kaplan updated Malaysian healthcare professionals on some of the recent clinical advances in the management of male lower urinary tract symptoms (LUTS).
In the practice of sexual medicine, the goal of the treating physician is to help the patient (or the couple) return to satisfactory sexual relations. Healthy sexual activity is important, and many, including the elderly population, report of regular sexual activity.1,2 Erectile dysfunction is an important aspect of sexual health that often goes undetected. Crucial barriers to ED discussion in the clinic are patients’ embarrassment or reluctance to discuss the condition and the lack of knowledge or training on the physicians’ side.3
Men with lower urinary tract symptoms (LUTS) are also found to be suffering from erectile dysfunction (ED), and studies show tadalafil 5 milligram once daily is safe and effective for the treatment of both LUTS due to benign prostate hyperplasia (BPH) plus coexisting ED.
During the Pharmacy Academy: The Pharmacist’s Role in Improving Patient Care held in Kuala Lumpur on the 8th of August, 2014, various expert speakers presented practical information and gave useful tips that pharmacists can use for their role in patient care.
In patients with nocturnal urgency secondary to overactive bladder (OAB) and low nocturnal bladder capacity, a mismatch between nocturnal urine production and bladder capacity may predict response to treatment with fesoterodine, according to a study. Symptom improvement appears to be mediated by increases in typical rather than maximum nocturnal voided volumes and be associated with improved quality of life.
Older patients with overactive bladder (OAB) appear to have increased frailty compared with individuals seeking care for other nononcologic urologic diagnosis, with frailty being a significant predictor of OAB, a study has found.
The quantity of uric acid stones has significantly increased in recent decades, according to a recent study. There are proportionately more female calcium stone formers but not uric acid stone formers with time. Furthermore, the most prominent factor distinguishing uric acid from calcium stones is urinary pH.